van Breeschoten J, Wouters MWJM, Hilarius DL, Haanen JB, et al. First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAF(V600)-mutant advanced melanoma patients: a propensity-matched survival analysis. Br J Cancer 2021 Jan 26. pii: 10.1038/s41416-020-01229.
PMID: 33495600